<DOC>
	<DOCNO>NCT01223768</DOCNO>
	<brief_summary>To assess clinical efficacy ALC treatment severe hepatic encephalopathy ( grade 3 West Haven grade scale ) , perform randomise , double blind placebo-controlled study administer ALC cirrhotic patient , evaluate effect ammonia level performance cognitive function .</brief_summary>
	<brief_title>Acetyl-L-Carnitine In Severe Hepatic Encephalopathy</brief_title>
	<detailed_description />
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Acetylcarnitine</mesh_term>
	<criteria>patient severe hepatic encephalopathy ( grade 3 West Haven grade scale ) hepatic cirrhosis Patients history recent alcohol abuse , patient use psychotropic drug ( e.g. , antipsychotic , interferon , benzodiazepine , antiepileptic , sedatives antidepressant ) Other exclusion criterion follow : major complication portal hypertension , gastrointestinal blood loss , hepatorenal syndrome bacterial peritonitis ; acute superimpose liver injury ; patient metabolic disorder diabetes mellitus , unbalanced heart failure and/or respiratory failure endstage renal disease ; additional precipitating factor high protein intake ( additional highprotein meal ) , constipation ; illiteracy .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2000</verification_date>
</DOC>